197 related articles for article (PubMed ID: 38043492)
41. Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions.
Jiang ZY; Lu MC; You QD
J Med Chem; 2016 Dec; 59(24):10837-10858. PubMed ID: 27690435
[TBL] [Abstract][Full Text] [Related]
42. The principal molecular mechanisms behind the activation of Keap1/Nrf2/ARE pathway leading to neuroprotective action in Parkinson's disease.
Chakkittukandiyil A; Sajini DV; Karuppaiah A; Selvaraj D
Neurochem Int; 2022 Jun; 156():105325. PubMed ID: 35278519
[TBL] [Abstract][Full Text] [Related]
43. Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate.
Satoh T; Lipton S
F1000Res; 2017; 6():2138. PubMed ID: 29263788
[TBL] [Abstract][Full Text] [Related]
44. Overexpression of miR-200a protects cardiomyocytes against hypoxia-induced apoptosis by modulating the kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 signaling axis.
Sun X; Zuo H; Liu C; Yang Y
Int J Mol Med; 2016 Oct; 38(4):1303-11. PubMed ID: 27573160
[TBL] [Abstract][Full Text] [Related]
45. Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development.
Robledinos-Antón N; Fernández-Ginés R; Manda G; Cuadrado A
Oxid Med Cell Longev; 2019; 2019():9372182. PubMed ID: 31396308
[TBL] [Abstract][Full Text] [Related]
46. A bioactive ligand-conjugated iridium(III) metal-based complex as a Keap1-Nrf2 protein-protein interaction inhibitor against acetaminophen-induced acute liver injury.
Li G; Liu H; Feng R; Kang TS; Wang W; Ko CN; Wong CY; Ye M; Ma DL; Wan JB; Leung CH
Redox Biol; 2021 Dec; 48():102129. PubMed ID: 34526248
[TBL] [Abstract][Full Text] [Related]
47. Ellagic acid activates the Keap1-Nrf2-ARE signaling pathway in improving Parkinson's disease: A review.
Wang Q; Botchway BOA; Zhang Y; Liu X
Biomed Pharmacother; 2022 Dec; 156():113848. PubMed ID: 36242848
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of the NRF2/KEAP1 Axis: A Promising Therapeutic Strategy to Alter Redox Balance of Cancer Cells.
Panieri E; Saso L
Antioxid Redox Signal; 2021 Jun; 34(18):1428-1483. PubMed ID: 33403898
[No Abstract] [Full Text] [Related]
49. Discovery of Keap1-Nrf2 small-molecule inhibitors from phytochemicals based on molecular docking.
Li M; Huang W; Jie F; Wang M; Zhong Y; Chen Q; Lu B
Food Chem Toxicol; 2019 Nov; 133():110758. PubMed ID: 31412289
[TBL] [Abstract][Full Text] [Related]
50. Dimethyl fumarate suppresses Theiler's murine encephalomyelitis virus-induced demyelinating disease by modifying the Nrf2-Keap1 pathway.
Kobayashi K; Tomiki H; Inaba Y; Ichikawa M; Kim BS; Koh CS
Int Immunol; 2015 Jul; 27(7):333-44. PubMed ID: 25721871
[TBL] [Abstract][Full Text] [Related]
51. An updated patent review of Nrf2 activators (2020-present).
Zhao Z; Dong R; Cui K; You Q; Jiang Z
Expert Opin Ther Pat; 2023 Jan; 33(1):29-49. PubMed ID: 36800917
[TBL] [Abstract][Full Text] [Related]
52. Kelch-like ECH-associated protein 1 (KEAP1) differentially regulates nuclear factor erythroid-2-related factors 1 and 2 (NRF1 and NRF2).
Tian W; Rojo de la Vega M; Schmidlin CJ; Ooi A; Zhang DD
J Biol Chem; 2018 Feb; 293(6):2029-2040. PubMed ID: 29255090
[TBL] [Abstract][Full Text] [Related]
53. Role of the Keap1/Nrf2 pathway in neurodegenerative diseases.
Yamazaki H; Tanji K; Wakabayashi K; Matsuura S; Itoh K
Pathol Int; 2015 May; 65(5):210-9. PubMed ID: 25707882
[TBL] [Abstract][Full Text] [Related]
54. Ginsenoside CK targeting KEAP1-DGR/Kelch domain disrupts the binding between KEAP1 and NRF2-DLG motif to ameliorate oxidative stress damage.
Cheng C; Zhang J; Liu K; Xu Y; Shen F; Han Y; Hou Y; Zhang T; Bai G
Phytomedicine; 2023 Oct; 119():154992. PubMed ID: 37499433
[TBL] [Abstract][Full Text] [Related]
55. Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2 system during cellular stress.
Suzuki T; Yamamoto M
J Biol Chem; 2017 Oct; 292(41):16817-16824. PubMed ID: 28842501
[TBL] [Abstract][Full Text] [Related]
56. Advances in developing noncovalent small molecules targeting Keap1.
Barreca M; Qin Y; Cadot MEH; Barraja P; Bach A
Drug Discov Today; 2023 Dec; 28(12):103800. PubMed ID: 37852355
[TBL] [Abstract][Full Text] [Related]
57. Molecular recognition between potential natural inhibitors of the Keap1-Nrf2 complex.
Bello M; Morales-González JA
Int J Biol Macromol; 2017 Dec; 105(Pt 1):981-992. PubMed ID: 28746889
[TBL] [Abstract][Full Text] [Related]
58. Sp1 is a substrate of Keap1 and regulates the activity of CRL4A
Siswanto FM; Oguro A; Imaoka S
J Biol Chem; 2021; 296():100704. PubMed ID: 33895141
[TBL] [Abstract][Full Text] [Related]
59. Peptide and small molecule inhibitors of the Keap1-Nrf2 protein-protein interaction.
Wells G
Biochem Soc Trans; 2015 Aug; 43(4):674-9. PubMed ID: 26551711
[TBL] [Abstract][Full Text] [Related]
60. Dimethylfumarate alleviates early brain injury and secondary cognitive deficits after experimental subarachnoid hemorrhage via activation of Keap1-Nrf2-ARE system.
Liu Y; Qiu J; Wang Z; You W; Wu L; Ji C; Chen G
J Neurosurg; 2015 Oct; 123(4):915-23. PubMed ID: 25614941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
